PROPOSAL TEMPLATE. Patent Duration and Collusive Behaviour to Postpone R&D for Innovative Treatments
|
|
- Walter Benson
- 5 years ago
- Views:
Transcription
1 PROPOSAL TEMPLATE Proposal Name: Patent Duration and Collusive Behaviour to Postpone R&D for Innovative Treatments Submitted by: Pr. Patrick Leoni - Euromed Management (France) patrick.leoni@euromed-management.com Pr. Alvaro Sandroni Kellogg School of Management, Northwestern U. (USA) sandroni@kellogg.northwestern.edu Description of the proposal This project identifies a key strategic deterrent to initiate R&D for innovative treatments. We argue that the current patent system induces, at industry level, collusive behavior to postpone R&D for innovative treatments. We recommend the reduction of patents duration to prevent collusion at industry level, while maintaining minimal incentives to initiate R&D. We consider the case of many pharmaceutical firms, each owning a large pool of patents to treat some aspects/symptoms of a specific disease as well patents on other diseases for which they compete. Those firms are capable of engaging into a R&D race for an innovative treatment; if successful, this treatment eventually seizes
2 the whole market for treating this disease and it renders the whole set of existing patents obsolete. A typical example is HIV/AIDS, where over 2000 patents for available treatments are owned by few firms, and limited efforts to develop a therapeutic vaccine have been observed. We argue that, unless the market size is big enough, there is a collusive equilibrium among the industry to postpone R&D for the innovative treatment whenever the time horizon of the current patents is long enough. We also argue that, as the average time horizon of those patents decreases, the stability of this collusive equilibrium for postponing R&D decreases until it becomes optimal to unilaterally start the R&D. We thus point out that there exists a minimal patent duration below which no collusion for postponing R&D is possible. Moreover, this minimal patent duration is independent (to a large extent) of market returns, but it corresponds instead to the minimal financial incentive to reward innovation. This collusive behavior is thus dependant on the legal requirement for patent duration, and reducing enough the duration fosters R&D race. Our theory is consistent with observed episodes in the pharmaceutical industry. 2
3 Describe and justify the potential public health impact 1 of the proposal: The proposal aims at fostering R&D for innovative treatments, by designing stronger financial incentives to pharmaceutical companies to initiate R&D race. The consequences thus are 1- Potential public health impact in developing countries Early availability of innovative treatments 2- Potential for de-linking R&D costs and price of products Price of products are irrelevant to a firm seeking to maintain its market power through innovation. 3- Impact on capacity building in, and transfer of technology to, developing countries Generics are available sooner to developing countries thanks to a lower patent duration Describe and justify the technical feasibility 2 of the proposal: Basically, changing the regulations for pharmaceutical products at international level is needed. This involves negotiations with WTO to coordinate this effort across countries Describe and justify the financial feasibility 3 of the proposal: There is no direct cost to the regulator, except the cost of engaging negotiations with the parties. The cost is on the pharmaceutical companies, which will mower the return on their current pool of patents Describe in what way the proposal addresses cross-cutting issues 4 : The proposal indirectly allows generics to be available sooner to developing countries. It is compatible with, and adds to every other effort to foster availability of innovative treatments. 1 Principally CEWG criterion 1 but others may be relevant e.g. Equity/distributive effect including on availability and affordability of products and impact on access and delivery. 2 Principally CEWG criterion 4 but others may be relevant e.g. Rational and equitable use of resources/efficiency considerations 3 Principally CEWG criterion 5 but others may be relevant e.g. Cost-effectiveness. 4 Cross-cutting Issues refers principally to CEWG criteria 7-12, if not addressed elsewhere in the submission e.g. Potential for delinking R&D costs and price of products. 3
4 Identify key steps necessary to begin implementation and key issues to be resolved for implementation to begin: The project requires to modify the whole legislation on patent rights, so as to reduce patent duration. The legal work may be extensive, and reluctance from pharmaceutical companies is to be expected. Provide the evidence base for the proposal including literature references and other relevant information: The proposal is based on a working paper by the 2 authors, entitled Can Patent Duration Hinder Medical Innovation for Neglected Diseases? Additional references are given below: [1] American Pharmaceutical Research Companies (2007) Pharmaceutical researchers are testing 92 medicines and vaccines for HIV and related conditions. Report on Medicines in Development for HIV/AIDS. [2] Bain, J. (1956) Barriers to New Competition. Cambridge, MA: Harvard University Press. [3] Borrell, J.-R. (2007) Pricing and patents of HIV/AIDS drugs in developing countries. Applied Economics 39, [4] Chamberlin, E. (1933) Theory of Monopolistic Competition. Cambridge, MA: Harvard University Press. [5] Grabowski, H. (2003) Innovation and R&D incentives for orphan drugs and neglected diseases. Mimeo, Duke University. [6] Grabowski, H. and J. Vernon (1992) Brand loyalty, entry and price competition in pharmaceuticals after the 1984 drug act. Journal of Law and Economics 35, [7] Hudson, J. (2000) Take-up in the pharmaceutical market following patent expiry: A multi-country study. International Review of Law and Economics 24, [8] Ito, B. and T. Yamagata (2005) Who develops innovations in medicine for the poor? Trends in patent applications related to medicines for HIV/AIDS, tuberculosis, malaria and neglected diseases. Institute of Developing Economies working paper 24. [9] Klausner, R.D. et al. (2003) The need for a global HIV vaccine enterprise. Science 300,
5 [10] Kremer, M. and R. Glennerster (2004) Strong Medicine: Creating Incentives For Pharmaceutical Research On Neglected Diseases. Princeton University Press. [11] Lamptey, P., Johnson, J. and M. Khan (2006) The global challenge of HIV and AIDS. Population Bulletin 6, University of Stellenbosch. [12] Leibowitz, A. and N. Sood (2007) Market power and state costs of HIV/AIDS drugs. International Journal of Health Care Finance and Economics 7, [13] Leoni, P. (2010) Economic Challenges in the Fight against HIV/AIDS. Nova Science Publishers. [14] Matsushima, H. (2001) Multimarket Contact, Imperfect Monitoring, and Implicit Collusion. Journal of Economic Theory 98, [15] Tirole, J. (1988) The Theory of Industrial Organization. MIT Press. [16] Sherer, F. (1980) Industrial Market Structure and Economic Performance (2nd edition). Chicago: Rand-McNally. [17] United States Patent and Trademark Office (1998) Lehman to leave Patent and Trademark Office by the end of the year. Online: 5
Standing Committee on the Law of Patents
E SCP/24/4 ORIGINAL: ENGLISH DATE: JUNE 29, 2016 Standing Committee on the Law of Patents Twenty-Fourth Session Geneva, June 27 to 30, 2016 PROPOSAL BY THE AFRICAN GROUP FOR A WIPO WORK PROGRAM ON PATENTS
More informationLocal Production of Pharmaceuticals and Related Technology Transfer UNCTAD/CD-TFT 1. Background
Local Production of Pharmaceuticals and Related Technology Transfer Dr. Padmashree Gehl Sampath Division for Technology and Logistics UNCTAD UNCTAD/CD-TFT 1 1 Background Case studies part of the EU funded
More informationAn Essential Health and Biomedical R&D Treaty
An Essential Health and Biomedical R&D Treaty Submission by Health Action International Global, Initiative for Health & Equity in Society, Knowledge Ecology International, Médecins Sans Frontières, Third
More informationGlobal strategy and plan of action on public health, innovation and intellectual property
SIXTY-FIRST WORLD HEALTH ASSEMBLY WHA61.21 Agenda item 11.6 24 May 2008 Global strategy and plan of action on public health, innovation and intellectual property The Sixty-first World Health Assembly,
More informationB) Issues to be Prioritised within the Proposed Global Strategy and Plan of Action:
INTERGOVERNMENTAL WORKING GROUP ON PUBLIC HEALTH, INNOVATION AND INTELLECTUAL PROPERTY EGA Submission to Section 1 Draft Global Strategy and Plan of Action The European Generic Medicines Association is
More informationPatents & Innovation In the Pharmaceutical Industry: Literature Review. Jonathan Gock POL 459 Prof. Hira Fall 09
Patents & Innovation In the Pharmaceutical Industry: Literature Review Jonathan Gock POL 459 Prof. Hira Fall 09 1 Introduction In light of recent health epidemics (e.g. H1N1) and the reality of an ever-aging
More informationDraft Plan of Action Chair's Text Status 3 May 2008
Draft Plan of Action Chair's Text Status 3 May 2008 Explanation by the Chair of the Drafting Group on the Plan of Action of the 'Stakeholder' Column in the attached table Discussed Text - White background
More informationDraft global strategy on public health, innovation and intellectual property
IGWG: Outcome document at 14.00 hours, Saturday 3 May 2008 Draft global strategy on public health, innovation and intellectual property The context 1. In resolution WHA59.24 the Health Assembly recognized
More informationElements of a global strategy and plan of action
INTERGOVERNMENTAL WORKING GROUP A/PHI/IGWG/1/5 ON PUBLIC HEALTH, INNOVATION AND 8 December 2006 INTELLECTUAL PROPERTY Agenda item 2.3 Elements of a global strategy and plan of action Progress to date in
More informationACCOUNTING TREATMENT OF INTELLECTUAL PROPERTY IN THE PHARMACEUTICAL INDUSTRY
Trakia Journal of Sciences, Vol. 9, No 4, pp 63-68, 2011 Copyright 2011 Trakia University Available online at: http://www.uni-sz.bg ISSN 1313-7069 (print) ISSN 1313-3551 (online) Original Contribution
More information70 th World Health Assembly May 2017 MSF Briefing on Medical Research and Development
70 th World Health Assembly May 2017 MSF Briefing on Medical Research and Development Overview Médecins Sans Frontières (MSF) welcomes the increased attention by WHO and Member States to find ways to ensure
More informationInternational IP. Prof. Eric E. Johnson. General Principles
International IP Prof. Eric E. Johnson ericejohnson.com General Principles territoriality Dependence, independence, central attack Procedural harmonization Substantive agreements National treatment Minima
More informationA NEW INCENTIVE SYSTEM FOR TECHNOLOGICAL INNOVATION IN DEVELOPING COUNTRIES
A NEW INCENTIVE SYSTEM FOR TECHNOLOGICAL INNOVATION IN DEVELOPING COUNTRIES Miguel A. Maito Eduardo Franciosi Introduction This work has been inspired by the analysis and discussion of Professor Joseph
More informationDr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board
Dr. Biswajit Dhar Professor, Jawaharlal Nehru University, India and Member DA9 Advisory Board Intellectual Property Rights in Preferential Trade Agreements Many Preferential Trade Agreements (PTAs) adopted
More information"Competition Policy and Intellectual Property Rights in the Republic of Latvia since 1991" (the working title)
"Competition Policy and Intellectual Property Rights in the Republic of Latvia since 1991" (the working title) Research Proposal for the Doctoral Course at the "Ostsee-Kolleg: Baltic Sea School Berlin",
More informationIntellectual Property
Intellectual Property Johnson & Johnson believes that the protection of intellectual property (IP) is essential to rewarding innovation and promoting medical advances. We are committed: to raising awareness
More information31 August Background
31 August 2012 Written submission of Knowledge Ecology International (KEI) to the French Ministry of Foreign Affairs to the national consultation on financing and coordination of research and development
More informationIntellectual Property Policy. DNDi POLICIES
Intellectual Property Policy DNDi POLICIES DNDi hereby adopts the following intellectual property (IP) policy: I. Preamble The mission of DNDi is to develop safe, effective and affordable new treatments
More informationThinking About Technology Policy: Market Failures versus Innovation systems
Institute for Innovation and Public Purpose Thinking About Technology Policy: Market Failures versus Innovation systems Richard R Nelson George Blumenthal Professor of International and Public Affairs,
More informationUsing Academic Licensing Agreements to Promote Global Social Responsibility
Using Academic Licensing Agreements to Promote Global Social Responsibility Equitable Licensing of Medical Research Results Charité - Universitätsmedizin Berlin April 26, 2009 Dr. Ashley J. Stevens Executive
More informationCreating a more open, inclusive and equitable innovation system.
Creating a more open, inclusive and equitable innovation system Richard Jefferson July 14, 2009, Conference on Intellectual Property and Public Policy Issues www.openinnovation.org Questions (Agriculture):
More informationWTO NEGOTIATIONS ON TRIPS AND PUBLIC HEALTH: AN OVERVIEW. Jayashree Watal WTO Secretariat
WTO NEGOTIATIONS ON TRIPS AND PUBLIC HEALTH: AN OVERVIEW Jayashree Watal WTO Secretariat Outline Background to discussions in the TRIPS Council, including WHO-WTO Workshop on Differential Pricing and Financing
More informationStatement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL PROPERTY PROTECTION ON INNOVATION AND TECHNOLOGY DEVELOPMENT
Business and Industry Advisory Committee to the OECD OECD Comité Consultatif Economique et Industriel Auprès de l l OCDE Statement by the BIAC Committee on Technology and Industry on THE IMPACT OF INTELLECTUAL
More informationUNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview
UNITAID The HIV/AIDS Medicines Patent Pool Initiative Overview December 2009 UNITAID Mission UNITAID's Mission Scale up access to treatment for HIV/AIDS, malaria and TB Leverage price reductions of quality
More informationMedical Innovation Changing Business Models. Geneva, 5 July 2013
Medical Innovation Changing Business Models (A joint technical symposium by WHO, WIPO and WTO) Geneva, 5 July 2013 Richard Wilder Associate General Counsel Global Health Funding Options and IP Grants:
More informationMEDICINES ACCESS AND INNOVATION IN DEVELOPING COUNTRIES. A Review by Europe Economics
MEDICINES ACCESS AND INNOVATION IN DEVELOPING COUNTRIES A Review by Europe Economics Europe Economics Chancery House 53-64 Chancery Lane London WC2A 1QU Tel: (+44) (0) 20 7831 4717 Fax: (+44) (0) 20 7831
More informationAlternatives to the patent system used to support R&D Efforts. James Love WIPO Expert Forum on International Technology Transfer February 17, 2015
Alternatives to the patent system used to support R&D Efforts James Love WIPO Expert Forum on International Technology Transfer February 17, 2015 Some conclusions {p1} The grant of exclusive rights to
More informationCompulsory Licensing:
HESO 449B Compulsory Licensing: An effective tool to increasing access to essential medicines? Julia Wu Submitted on April 7 th, 2010 Realizing that patent protection on pharmaceutical products can restrict
More informationUNITAID s approach to funding innovations in TB diagnosis and treatment Robert Matiru & Janet Ginnard, UNITAID Geneva, 29 April 2015
UNITAID UNITAID s approach to funding innovations in TB diagnosis and treatment Robert Matiru & Janet Ginnard, UNITAID Geneva, 29 April 2015 Page 2 UNITAID's role in the global response By connecting the
More informationEconomics of IPRs and patents
Economics of IPRs and patents TIK, UiO 2016 Bart Verspagen UNU-MERIT, Maastricht verspagen@merit.unu.edu 3. Intellectual property rights The logic of IPRs, in particular patents The economic design of
More informationExecutive Summary. Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination
Executive Summary Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination Report of the Consultative Expert Working Group on Research and
More informationINSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH
INSTITUTE OF MEDICINE COMMITTEE ON THE U.S. COMMITMENT TO GLOBAL HEALTH Sharing Information, Knowledge and Materials Dr. Ashley J. Stevens Executive Director, Technology Transfer Senior Research Associate
More informationSynergies and Complementarities with EU Research & Innovation Policy
Synergies and Complementarities with EU Research & Innovation Policy Information Day - EIT 2014 Bernard Mulligan Petra Leroy Cadova Peter Wintlev-Jensen European Commission Budapest, 14 March 2014 Why
More informationFixing Canada s Access to Medicines Regime (CAMR): 20 Questions & Answers
Fixing Canada s Access to Medicines Regime (CAMR): 20 Questions & Answers In this document: Questions 1 to 4 give a quick overview of CAMR and why it needs to be fixed. Questions 5 to 11 provide more in-depth,
More informationThe case for quality
The case for quality Around the world, up to two billion people lack access to quality essential medicines. Poor-quality medicines undermine the treatment of some of the world s most pressing diseases,
More informationTapan Ray Director General Organisation of Pharmaceutical Producers of India ALCAN PACKAGING UNIVERSITY OCT 8, LONAVALA
COMBATING COUNTERFEIT DRUGS WITH PACKAGING TECHNOLOGY Tapan Ray Director General Organisation of Pharmaceutical Producers of India ALCAN PACKAGING UNIVERSITY OCT 8, 2009 -LONAVALA Content Counterfeit Medicines:
More informationPatients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry
Patients Must Have Immediate Access to Affordable Generic Medicines at Day One After Patent Expiry Generic Medicines: Key to Healthcare Sustainability and Patient Care EGA represents over 700 companies
More informationCHAPTER LEARNING OUTCOMES. By the end of this section, students will be able to:
CHAPTER 4 4.1 LEARNING OUTCOMES By the end of this section, students will be able to: Understand what is meant by a Bayesian Nash Equilibrium (BNE) Calculate the BNE in a Cournot game with incomplete information
More informationWIPO-WASME Program on Practical Intellectual Property Rights Issues for Entrepreneurs, Economists, Bankers, Lawyers and Accountants
WIPO-WASME Program on Practical Intellectual Property Rights Issues for Entrepreneurs, Economists, Bankers, Lawyers and Accountants Topic 12 Managing IP in Public-Private Partnerships, Strategic Alliances,
More informationCOPYCAT - CASE 1 COPYCAT - CASE 2
BER Case 93-1 APPROVED June 16, 1993 Section II.4. Section III.5.a. Section III.8.c. Section III.10. Section III.11. COPYCAT - CASE 1 FACTS: Engineer A, a registered professional engineer, has worked on
More informationConference. Intellectual property and sustainable development: what are the winning initiatives?
Conference Intellectual property and sustainable development: what are the winning initiatives? North / South exchanges, innovation and sustainable development, corporate social and environmental responsibility,
More informationInnovation and Equitable Access to Medicines: A New Global Framework for R&D
Innovation and Equitable Access to Medicines: A New Global Framework for R&D Seminar at SOAS, University of London 24 October 2013 Suerie Moon, MPA, PhD Research Director & Co-Chair, Forum on Global Governance
More informationPublic Hearings Concerning the Evolving Intellectual Property Marketplace
[Billing Code: 6750-01-S] FEDERAL TRADE COMMISSION Public Hearings Concerning the Evolving Intellectual Property Marketplace AGENCY: Federal Trade Commission. ACTION: Notice of Public Hearings SUMMARY:
More informationTRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY ACCESS TO MEDICINE: Exploitation of pharmaceutical patents: compulsory licences SESSION 4
TRAINING SEMINAR PHARMACEUTICALS AND INTELLECTUAL PROPERTY 1 12 14 March 2012 Pretoria, South Africa SESSION 4 ACCESS TO MEDICINE: COMMERCIALISATION, DISTRIBUTION, COMPETITION ----------------- Exploitation
More informationAfrican Civil Society Meeting
African Civil Society Meeting Intergovernmental Working Group on Intellectual Property, Innovation and Health Topic: Considering Domestic Manufacturing Issues Nairobi Kenya 28-29 August 2007 DR W.O. WANYANGA
More informationLEGAL TECH NEWSLETTER FEBRUARY 2015
LEGAL TECH NEWSLETTER FEBRUARY 2015 Can Computers Practice Law? By Nina Cunningham Can computers practice law? Many are inclined to say yes when using them affects us in so many ways. When scanning the
More informationCourse Overview J-PAL HOW TO RANDOMIZE 2
How to Randomize Course Overview 1. What is Evaluation? 2. Measurement & Indicators 3. Why Randomize? 4. How to Randomize? 5. Sampling and Sample Size 6. Threats and Analysis 7. Generalizability 8. Project
More information28 March Report of the Working Group on Pharmaceuticals and Public Health of the High Level Committee on Health.
PHARMACEUTICALS AND PUBLIC HEALTH IN THE EU: PROPOSALS TO THE HIGH LEVEL COMMITTEE ON HEALTH FOR POLICIES AND ACTIONS IN THE FRAMEWORK OF THE TREATY OF AMSTERDAM a) 28 March 2000 a) Report of the Working
More informationVirtual Mentor American Medical Association Journal of Ethics December 2006, Volume 8, Number 12:
Virtual Mentor American Medical Association Journal of Ethics December 2006, Volume 8, Number 12: 834-838. Health law Intellectual property and access to medicine for the poor by Tara Leevy, LLB, LLM India
More informationAccess to Technology in the Post-2015 Development Agenda. Alessandra Casazza Policy Advisor UNDP Asia-Pacific Regional Center
Access to Technology in the Post-2015 Development Agenda Alessandra Casazza Policy Advisor UNDP Asia-Pacific Regional Center TECHNOLOGY IS ESSENTIAL FOR ACHIEVING SUSTAINABLE DEVELOPMENT MDG 8 ICT & Access
More informationDesigning an ethical complement to the patent regime for pharmaceutical innovation. Pharma-Innovation Patent-2
Designing an ethical complement to the patent regime for pharmaceutical innovation Innova-P2 Project Background Innova-P2 is a 3-year Collaborative Project funded by the European Community s Seventh Framework
More informationASSOCIATION INTERNATIONALE DE LA MUTUALITE. Pharmaceutical Sector Inquiry Preliminary Report 28 November AIM Response 2 February 2009
AIM ASSOCIATION INTERNATIONALE DE LA MUTUALITE Pharmaceutical Sector Inquiry Preliminary Report 28 November 2008 AIM Response 2 February 2009 AIM would like to thank DG Competition for having taken the
More informationWHO workshop on IP and Vaccines. Geneva 19 th -20 th April Introduction to the IP issues Christopher Garrison Consultant to WHO
WHO workshop on IP and Vaccines Geneva 19 th -20 th April 2004 Introduction to the IP issues Christopher Garrison Consultant to WHO Vaccine access, R&D and technology transfer issues are intimately linked
More informationDiscovery: From Concept to the Patient - The Business of Medical Discovery. Todd Sherer, Ph.D.
Discovery: From Concept to the Patient - The Business of Medical Discovery Todd Sherer, Ph.D. Associate Vice President for Research and Director of OTT President Elect, Association of University Technology
More informationRegulation on medicinal products for paediatric use
Regulation on medicinal products for paediatric use ANWALTSKANZLEI STRÄTER Burkhard Sträter Kronprinzenstraße 20 53173 Bonn Tel.:++49-228 228-93454 93454-0 Fax.:++49-228 228-93454 93454-54 Mail@kanzleistraeter
More informationCarnegie Endowment for International Peace
Carnegie Endowment for International Peace How the U.S. and India could Collaborate to Strengthen Their Bilateral Relationship in the Pharmaceutical Sector Second Panel: Exploring the Gilead-India Licensing
More informationCertificate of Global Health Completion & Credential Request Form
Student Name: SPH Department: Email Address: UMID: Expected Graduation Date: Phone Number: Please submit this completed form to Dani Koel at SPH.Certificate.Inquiries@umich.edu or in person to room 1730
More informationPharma - Biotech Collaborations: Optimizing Success, Minimizing Risk and Maintaining Alignment
Presenter: Randall Sunberg Morgan Lewis May 16, 2008 In cooper Biography Randall Sunberg partner Morgan Lewis, Princeton Phone: 609.919.6606 Randall B. Sunberg is a partner in Morgan Lewis's Business and
More informationStanding Committee on the Law of Patents
E SCP/18/INF/3 ORIGINAL: ENGLISH DATE: APRIL 11, 2012 Standing Committee on the Law of Patents Eighteenth Session Geneva, May 21 to 25, 2012 PATENTS AND HEALTH: COMMENTS RECEIVED FROM MEMBERS AND OBSERVERS
More informationHEIDI L. WILLIAMS Education Employment Professional activities Honors
HEIDI L. WILLIAMS MIT Department of Economics, 50 Memorial Drive, E52-440, Cambridge MA 02142 (617) 669-0577 heidiw@mit.edu http://econ-www.mit.edu/faculty/heidiw Education 2005 2010 PhD, Economics, Harvard
More informationDiscovery-Based Science and Open Source. Olga Buzovetsky Wesleyan University May 28,2008
Discovery-Based Science and Open Source Olga Buzovetsky Wesleyan University obuzovetsky@wesleyan.edu May 28,2008 Introduction My paper is about how the transition of scientific methodology to discovery
More informationExperimental Economics A EXPLORATIONS IN ECONOMIC HISTORY A FINANCE AND STOCHASTICS A FINANCIAL MANAGEMENT (el.
A+ Journals ACADEMY OF MANAGEMENT JOURNAL 0001-4273 A+ ACADEMY OF MANAGEMENT REVIEW 0363-7425 A+ ACCOUNTING ORGANIZATIONS AND SOCIETY 0361-3682 A+ ACCOUNTING REVIEW 0001-4826 A+ ADMINISTRATIVE SCIENCE
More informationTRIPS FLEXIBILITIES AND ACCESS TO MEDICINES
TRIPS FLEXIBILITIES AND ACCESS TO MEDICINES A European Approach Acknowledgements We are grateful to Ellen t Hoen for reviewing an earlier version of this brochure. Publisher Health Action International
More informationMedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017)
MedTech Europe position on future EU cooperation on Health Technology Assessment (21 March 2017) Table of Contents Executive Summary...3 The need for healthcare reform...4 The medical technology industry
More informationLife Sciences Outlook. Long Island 2016
Life Sciences Outlook Long Island 2016 Long Island The Long Island life sciences landscape will continue to fuel the economy as firms emerge from Cold Spring Harbor Laboratory in Nassau County, as well
More informationProblems and Prospects of the Development of Import Substitution in Pharmaceutical Industry of the Russian Federation
Problems and Prospects of the Development of Import Substitution in Pharmaceutical Industry of the Russian Federation Doi:10.5901/mjss.2016.v7n1s1p121 Abstract Larisa Kiseleva Perm branch of the Russian
More informationWhy is US Productivity Growth So Slow? Possible Explanations Possible Policy Responses
Why is US Productivity Growth So Slow? Possible Explanations Possible Policy Responses Presentation to Brookings Conference on Productivity September 8-9, 2016 Martin Neil Baily and Nicholas Montalbano
More information38 th Board Meeting. Appointment of the Executive Director GF/B38/02. Board Decision November 2017, Geneva, Switzerland
38 th Board Meeting Appointment of the Executive Director 14-15 November 2017, Geneva, Switzerland Board Decision PURPOSE: This paper presents one decision point: the appointment of the Executive Director.
More informationOrganisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development
Unclassified DAF/COMP/M(2014)2/ANN6/FINAL DAF/COMP/M(2014)2/ANN6/FINAL Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 10-Feb-2015
More informationGermany s contribution to the United Nations Secretary-General s High-Level Panel on Access to Medicines
Berlin, 26 February 2016 Germany s contribution to the United Nations Secretary-General s High-Level Panel on Access to Medicines ONLINE SUBMISSION Section 1: Abstract Briefly describe your contribution:
More informationFree Trade Agreements on Public Health
UNDP, UNAIDS Issue BRIEF 2012 The Potential Impact of Free Trade Agreements on Public Health The Potential Impact of Free Trade Agreements on Public Health UNDP, UNAIDS UNAIDS / JC2349E (English original,
More informationAccess to Medicines, Patent Information and Freedom to Operate
TECHNICAL SYMPOSIUM DATE: JANUARY 20, 2011 Access to Medicines, Patent Information and Freedom to Operate World Health Organization (WHO) Geneva, February 18, 2011 (preceded by a Workshop on Patent Searches
More informationWhat Makes International Research Ethical (Or Unethical)? Eric M. Meslin, Ph.D Indiana University Center for Bioethics
What Makes International Research Ethical (Or Unethical)? Eric M. Meslin, Ph.D Indiana University Center for Bioethics Why Should We Care? Volume of health research is increasing more researchers, more
More informationTable Of Content. Stichting Health Action International... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...
Table Of Content... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D08 - HAI Europe Newsletter (EN)... 7 D01 - HAI Europe leaflet (EN)... 7 D02 - Briefing Papers and statements
More informationSCIENCE-INDUSTRY COOPERATION: THE ISSUES OF PATENTING AND COMMERCIALIZATION
SCIENCE-INDUSTRY COOPERATION: THE ISSUES OF PATENTING AND COMMERCIALIZATION Elisaveta Somova, (BL) Novosibirsk State University, Russian Federation Abstract Advancement of science-industry cooperation
More information12 December Peter Beyer Senior Advisor Essential Medicines & Health Products Switzerland
WIPO Standing Committee of the Law of Patents Information Exchange Session: Publicly accessible databases on patent information status and data on medicines and vaccines 12 December 2017 Peter Beyer Senior
More informationPresented by Doris Ma Fat on behalf of the. Department of Health Statistics and Information Systems World Health Organization, Geneva
Causes of death certification Presented by Doris Ma Fat (mafatd@who.int) on behalf of the Department of World Health Organization, Geneva at United Nations Sub-regional workshop on applying Principles
More information1. TRIPS, intellectual property rights and access to medicines a,b
UHC Technical brief 1. TRIPS, intellectual property rights and access to medicines a,b What is the TRIPS Agreement? The Agreement on Trade-Related Aspects of Intellectual Property Rights (or the TRIPS
More informationCharles River Associates Annual Conference 8 December 2010, Brussels Opening address: The interplay between law and economics
Charles River Associates Annual Conference 8 December 2010, Brussels Opening address: The interplay between law and economics Alexander ITALIANER Director General Directorate General for Competition European
More informationWhy is US Productivity Growth So Slow? Possible Explanations Possible Policy Responses
Why is US Productivity Growth So Slow? Possible Explanations Possible Policy Responses Presentation to Nomura Foundation Conference Martin Neil Baily and Nicholas Montalbano What is productivity and why
More informationRegional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities
DEPARTMENT OF INTELLECTUAL PROPERTY MINISTRY OF COMMERCE Regional Seminar on the Effective Implementation and Use of Several Patent-Related Flexibilities Topic 12: Which are Valid Grounds for a Compulsory
More informationDecision regarding PHARMAC s Implementation of Trans-Pacific Partnership (TPP) provisions and other Amendments to Application Processes
8 December 2016 Decision regarding PHARMAC s Implementation of Trans-Pacific Partnership (TPP) provisions and other Amendments to Application Processes PHARMAC is pleased to announce that changes will
More informationParliamentary Research Branch PATENT DEDICATION AND THE PATENTED MEDICINE PRICES REVIEW BOARD. Margaret Smith Law and Government Division
Mini-Review MR-136E PATENT DEDICATION AND THE PATENTED MEDICINE PRICES REVIEW BOARD Margaret Smith Law and Government Division 23 November 1995 Library of Parliament Bibliothèque du Parlement Parliamentary
More informationINTEGRATING INNOVATION AND CREATIVITY INTO NATIONAL POLICIES AND STRATEGIES OGADA T.
INTEGRATING INNOVATION AND CREATIVITY INTO NATIONAL POLICIES AND STRATEGIES OGADA T. High-Level Meeting for Members of Parliament of ARIPO Member States : Strategic Use of IP System for Economic, Cultural
More informationCommon evaluation criteria for evaluating proposals
Common evaluation criteria for evaluating proposals Annex B A number of evaluation criteria are common to all the programmes of the Sixth Framework Programme and are set out in the European Parliament
More informationMy name is Carsten Wald, I am freelancer in software developement and I would like to answer to your questions.
Dear Ladies and Gentlemen, My name is Carsten Wald, I am freelancer in software developement and I would like to answer to your questions. 1.1 Do you agree that these are the basic features required of
More informationIncentive Guidelines. Aid for Research and Development Projects (Tax Credit)
Incentive Guidelines Aid for Research and Development Projects (Tax Credit) Issue Date: 8 th June 2017 Version: 1 http://support.maltaenterprise.com 2 Contents 1. Introduction 2 Definitions 3. Incentive
More informationImplementing Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property in the Eastern Mediterranean Region
Implementing Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property in the Eastern Mediterranean Region 1 Table of Contents LIST OF ACRONYMS AND ABBREVIATIONS -----------------------------------------------------------------------------------
More informationIntroduction: What is Game Theory?
Microeconomics I: Game Theory Introduction: What is Game Theory? (see Osborne, 2009, Sect 1.1) Dr. Michael Trost Department of Applied Microeconomics October 25, 2013 Dr. Michael Trost Microeconomics I:
More informationApril 21, By to:
April 21, 2017 Mr. Qiu Yang Office of the Anti-Monopoly Commission Of the State Council of the People s Republic of China No. 2 East Chang an Avenue, Beijing P.R. China 100731 By Email to: qiuyang@mofcom.gov.cn
More informationIntellectual Property Initiatives
Intellectual Property Initiatives Customers Casio is actively promoting intellectual property activities in line with its management strategy through cooperation between its R&D and business divisions.
More informationPROTECTION OF INTELLECTUAL PROPERTY
Chapter 12 PROTECTION OF INTELLECTUAL PROPERTY OVERVIEW OF RULES In today s economic environment, intangible assets are becoming increasingly important. These assets, which are the result of human intellectual
More informationStrategic Management of Innovative Development of the Russian Pharmaceutical Complex
MPRA Munich Personal RePEc Archive Strategic Management of Innovative Development of the Russian Pharmaceutical Complex Natalia Klunko 2013 Online at https://mpra.ub.uni-muenchen.de/54381/ MPRA Paper No.
More informationDraft executive summaries to target groups on industrial energy efficiency and material substitution in carbonintensive
Technology Executive Committee 29 August 2017 Fifteenth meeting Bonn, Germany, 12 15 September 2017 Draft executive summaries to target groups on industrial energy efficiency and material substitution
More informationPromoting Innovation in Healthcare through the Patent System: The Bayh-Dole Act and the Orphan Drug Act
Promoting Innovation in Healthcare through the Patent System: The Bayh-Dole Act and the Orphan Drug Act Dominic Keating Office of International Relations United States Patent & Trademark Office Washington,
More informationAn Introduction to China s Science and Technology Policy
An Introduction to China s Science and Technology Policy SHANG Yong, Ph.D. Vice Minister Ministry of Science and Technology, China and Senior Fellow Belfer Center for Science and International Affairs
More informationWritten Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum
Written Submission for the Pre-Budget Consultations in Advance of the 2019 Budget By: The Danish Life Sciences Forum List of recommendations: Recommendation 1: That the government creates a Life Sciences
More informationSofosbuvir Patent Oppositions at European Patent Office
Challenging patent system in High Income Countries Sofosbuvir Patent Oppositions at European Patent Office Olivier Maguet Médecins du Monde, Drug Pricing Campaign WHS 2017, Sao Paulo, Options for countries
More informationTechnology Transfer and Climate Change: International Flows, Barriers and Frameworks
Brookings Global Economy and Development Climate Change Trade and Investment Washington, DC June 8, 2008 Technology Transfer and Climate Change: International Flows, Barriers and Frameworks 1 Dr. Brian
More informationTRIPS and Access to Medicines. WR Briefing
TRIPS and Access to Medicines WR Briefing Outline What is TRIPS How does it affect access to medicines What are the TRIPS flexibilities? What are extra-trips provisions? How do the extra-trips provisions
More information